Solventum CorporationNYSE: SOLV
Health Care · Health Care Technology
$75.58
+1.37%
Vol: 951K
Research Digest
Friday, June 19, 2026
Solventum resolves Delaware bylaw litigation and stock gains 6% over past month after Q1 2026 EPS of $1.48 beat the $1.34 estimate by 10%, with organic sales growth of 2.1% affirming full-year guidance.
Solventum (SOLV) resolved a Delaware bylaw litigation case in June 2026 — the company denied wrongdoing but agreed to pay $120,000 in attorneys' fees, with the court ordering case closure and disclosure via Form 8-K. The stock has gained 6% over the past month and 18% over three months, supported by Q1 2026 results where adjusted EPS of $1.48 beat the $1.34 estimate by 10% and revenue of $2.01 billion beat by 2%. The company posted 2.1% organic sales growth and affirmed full-year 2026 organic sales and free cash flow guidance. A new Executive Severance Plan filed via 8-K in May suggests governance activity at the leadership level. The 2026 EPS consensus estimate has been revised down from $2.38 to $2.04, indicating some analyst caution despite near-term beat momentum.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Solventum reported Q1 2026 adjusted EPS of $1.48 (+10.6%) beating $1.40 consensus on revenue of $2.01B, raised EPS guidance to high end of $6.40-$6.60 range, and received an Outperform initiation from Wedbush on May 15.Positive▶
The medical technology spin-off from 3M delivered organic sales growth of 2.1% driven by volume and new product launches. MedSurg organic sales rose 1.2% to $1.2B, Dental Solutions climbed 3.4% to $354M, and Health Information Systems grew 4.7% to $342M. Gross margin expanded 80 bps to 56.4%. Management affirmed full-year 2026 organic sales growth guidance of +2.0% to +3.0%. Wedbush initiated coverage with an Outperform rating on May 15, 2026. The Solventum Foundation also launched a national dental care access initiative with America's ToothFairy on May 14. Stock traded around $69.04 with consensus Moderate Buy rating and average PT of $80.33.
May 20Solventum beat Q1 estimates with adjusted EPS of $1.48, affirmed 2026 guidance toward the high end, and was initiated with an Outperform rating by Wedbush.Positive▶
Solventum reported Q1 2026 sales of $2.01B, down 3.0% reported but up 2.1% organically, with adjusted diluted EPS of $1.48 (up 10.6%) topping consensus estimates. MedSurg organic sales rose 1.2% to $1.2B, Dental Solutions grew 3.4% to $354M, and Health Information Systems grew 4.7% to $342M, while gross margin expanded 80 bps to 56.4%. GAAP net income fell to $13M from $137M due to portfolio actions and FX headwinds. The company affirmed full-year 2026 guidance with organic sales growth of +2.0% to +3.0% and adjusted EPS expected toward the high end of the $6.40-$6.60 range. Shares rose roughly 8.8% on the print, and Wedbush initiated coverage with an Outperform rating on May 15.
May 19Solventum beat Q1 2026 estimates with $1.48 adj EPS (+10.6% YoY) on $2.01B revenue, affirming full-year guidance.Mixed▶
Solventum reported Q1 2026 results on May 5 with adjusted diluted EPS of $1.48, up 10.6% YoY and 9.3% above consensus, on revenue of $2.007B. Organic sales growth was 2.1%, driven by volume and supported by new product launches. MedSurg organic sales rose 1.2% to $1.2B, Dental Solutions grew 3.4% to $354M, and Health Information Systems grew 4.7% to $342M. Gross margin expanded 80 bps to 56.4%. The company affirmed full-year 2026 guidance with organic sales growth of +2.0% to +3.0% and adjusted EPS toward the high end of $6.40-$6.60. On May 7, KeyBanc raised PT to $93 from $92; Stifel cut to $90 from $105; UBS cut to $78 from $82. The Solventum Foundation launched a national dental care access initiative on May 14.
May 18Solventum reported Q1 2026 results beating expectations with adjusted EPS of $1.48 (+10.6%), raised EPS guidance to high end of range, and continued $1B share repurchase program, with shares gaining 8.8%.Positive▶
Solventum reported Q1 2026 results on May 5 with adjusted diluted EPS of $1.48 (up 10.6%) and sales of $2.01B, beating market expectations despite a 3% YoY revenue decline. Organic sales grew 2.1% driven by volume and new product launches, with gross margin expanding 80 basis points to 56.4%. Management raised EPS guidance to the high end of $6.40-$6.60 range and affirmed full-year organic sales growth of +2.0% to +3.0%. Strategic milestones included ERP migration progress, commencement of a $1 billion share repurchase program, Acera acquisition integration, and ongoing P&F divestiture. The Transform for the Future $500M cost savings plan continued delivering benefits. Solventum participated in BofA Securities 2026 Healthcare Conference on May 7. Stock gained 8.8% post-earnings.
May 15Solventum Q1 FY26 EPS of $1.48 (+10.6%) beats; margins expand to 19.5% and $67M of $1B buyback executedPositive▶
Solventum reported Q1 FY26 on May 5, 2026 with revenue of $2.01B (+2.1% organic) and adjusted EPS of $1.48 (+10.6% YoY), beating consensus on both lines. Operating margin expanded to 19.5%. Solventum maintained FY26 organic growth guidance of 2-3% (3-4% ex-SKU rationalization) and EPS of $6.40-$6.60, with management guiding toward the high end. The company repurchased 923K shares for $67M under a $1B authorization and signaled accelerated repurchase pace. Key strategic moves: the purification & filtration (P&F) divestiture and the Acera acquisition expand presence in acute care synthetic tissue, with nearly 20 new product launches planned over the next two years. Solventum will participate in the 2026 BofA Securities Healthcare Conference. Risk: reported sales fell 3% YoY due to portfolio exits, with separation/restructuring costs still pressuring reported margins.
May 14Solventum extends 7-day rally up 13% as analysts adjust PTs after Q1 EPS beat and reaffirmed guidancePositive▶
Solventum stock just completed a rare 7-day winning streak with shares up 8.8% over the past week, breaking above its 200-day moving average to signal a long-term bullish trend. Q1 2026 results showed adjusted EPS up 10.4% to $1.48 with full-year guidance reaffirmed despite a 3% revenue decline. Recent analyst moves include KeyBanc raising PT to $93 from $92 (Overweight), Stifel lowering PT to $90 from $105 (Buy), and UBS cutting PT to $78 from $82 (Neutral). The 12-month consensus PT of $85.27 implies 18.76% upside. Solventum is also scheduled to participate in the 2026 BofA Securities Health Care Conference. The 3M spinoff continues integrating its $900M Acera Surgical acquisition into its MedSurg portfolio.
May 13Solventum rose 8.8% after Q1 beat with adjusted EPS of $1.48 (+10% YoY) and reaffirmed FY26 guidance of $6.40-$6.60 EPSPositive▶
Solventum reported Q1 2026 results on May 5, 2026, with adjusted EPS of $1.48 (up 10% YoY) on revenue of $2.01B. Organic sales grew 2.1%, driven by volume and new product launches. Gross margin expanded 80bps to 56.4%. The company reaffirmed FY26 adjusted EPS guidance of $6.40-$6.60 and highlighted ERP migration progress and commencement of a $1B share repurchase program. Acera acquisition integration and the P&F divestiture continue to advance. Analyst reactions were mixed: KeyBanc raised its target to $93 from $92, while Stifel lowered to $90 from $105. Solventum also announced participation in the 2026 BofA Securities Health Care Conference.
May 12No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| SOLVSOLVENTUM | $75.58 | +1.37% | -0.9% | 10.7x | 0.75 | $13.1B |
| LLYELI | $1,099.89 | -1.09% | +7.8% | 24.7x | 0.52 | $979.6B |
| JNJJOHNSON | $228.45 | -2.46% | -0.4% | 18.0x | 0.26 | $549.8B |
| ABBVABBVIE | $216.79 | -2.01% | +2.0% | 13.3x | 0.31 | $382.5B |
| UNHUNITEDHEALTH | $400.38 | +0.21% | +4.6% | 19.2x | 0.65 | $364.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.